HighTower Advisors LLC increased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 32.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,169 shares of the biopharmaceutical company’s stock after purchasing an additional 5,225 shares during the quarter. HighTower Advisors LLC’s holdings in TG Therapeutics were worth $822,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Magnetar Financial LLC acquired a new position in TG Therapeutics in the second quarter valued at approximately $208,000. PNC Financial Services Group Inc. lifted its holdings in TG Therapeutics by 116.3% in the second quarter. PNC Financial Services Group Inc. now owns 2,293 shares of the biopharmaceutical company’s stock valued at $89,000 after acquiring an additional 1,233 shares during the period. Swiss National Bank lifted its holdings in TG Therapeutics by 7.4% in the second quarter. Swiss National Bank now owns 258,200 shares of the biopharmaceutical company’s stock valued at $10,016,000 after acquiring an additional 17,900 shares during the period. Legato Capital Management LLC purchased a new stake in shares of TG Therapeutics in the second quarter valued at approximately $751,000. Finally, Teacher Retirement System of Texas increased its position in shares of TG Therapeutics by 18.0% in the second quarter. Teacher Retirement System of Texas now owns 13,507 shares of the biopharmaceutical company’s stock valued at $524,000 after buying an additional 2,060 shares in the last quarter. 67.14% of the stock is owned by hedge funds and other institutional investors.
Shares of TGTX opened at $30.70 on Tuesday. TG Therapeutics, Inc. has a one year low of $21.06 and a one year high of $56.74. The stock has a market capitalization of $4.34 billion, a price-to-earnings ratio of -11.29 and a beta of 2.11. The stock has a 50 day moving average price of $29.45 and a 200 day moving average price of $36.86.
TGTX has been the subject of a number of recent analyst reports. Zacks Investment Research cut TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 6th. HC Wainwright cut their price objective on TG Therapeutics from $89.00 to $84.00 and set a “buy” rating for the company in a research report on Monday, August 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, TG Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $69.25.
TG Therapeutics Company Profile
TG Therapeutics, Inc engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.
Featured Article: Trade War
Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX).
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.